This stock is no longer traded. It was delisted on July 9, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Petros Pharmaceuticals Inc. is a company specializing in the development and commercialization of pharmaceuticals in the field of men's health. Its primary focus is on treatments related to male sexual health, offering innovative solutions designed to enhance quality of life. Notable for its flagship product, Stendra, a prescription medication used to treat erectile dysfunction, Petros Pharmaceuticals aims to deliver impactful therapies that address significant medical needs. Operating within the broader pharmaceutical industry, the company works to expand its market reach through strategic partnerships, research and development initiatives, and novel product offerings. Its role in the market reflects a commitment to advancing health and wellness in specialized areas, contributing to the dynamic landscape of health care solutions. Headquartered in the United States, Petros Pharmaceuticals is an active player in the life sciences sector, continually exploring opportunities to innovate and lead in its specific niche.
Website1185 Avenue of the Americas
New York, NY, 10036
United States
Summary of Aug 15's posts. Generated by AI.
Summary of May 22's posts. Generated by AI.
Summary of May 21's posts. Generated by AI.
Investors talking about PTPI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.